Taisho Pharma (TAISF) 100.2050 $TAISF Attention
Post# of 273249
Posted On: 09/26/2016 9:02:25 AM
Taisho Pharma (TAISF) 100.2050 $TAISF
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxcczv/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Attention Deficit Hyperactivity Disorder (ADHD) Overview - Therapeutics Development - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - APeT Holding BV - Arbor Pharmaceuticals, LLC. - BCWorld Pharm Co. Ltd. - Collegium Pharmaceutical, Inc. - Curemark, LLC - Domain Therapeutics SA - DURECT Corporation - H. Lundbeck A/S - Heptares Therapeutics Limited - Highland Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Luc Therapeutics, Inc. - Medgenics Inc. - Merck & Co., Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Neurovance, Inc. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/jx...on_deficit
KMPH: 4.56 (+0.01), MDGN: 5.54 (+0.16), ADHD: 4.65 (-0.05), SUPN: 26.17 (+0.15), COLL: 15.48 (+0.18), DRRX: 1.70 (-0.04), NEOS: 7.14 (+0.25), NDRM: 17.37 (-0.38), MRK: 62.96 (-0.06), SHPG: 203.05 (-1.17), ITCI: 42.40 (+1.53)
Mycoplasma Pneumoniae Infections Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Tue Dec 29, 9:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/z8tvk9/mycoplasma) has announced the addition of the "Mycoplasma Pneumoniae Infections Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Mycoplasma Pneumoniae Infections Global Clinical Trials Review, H2, 2015" provides an overview of Mycoplasma Pneumoniae Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Mycoplasma Pneumoniae Infections. It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Cempra, Inc. - KYORIN Holdings, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Shenzhen Kexing Biotech Co., Ltd. - Pfizer Inc. - Fujifilm Holdings Corporation - Daiichi Sankyo Company, Limited For more information visit http://www.researchandmarkets.com/research/z8tvk9/mycoplasma
PFE: 34.26 (+0.11), CEMP: 25.21 (+0.61)
Acute Upper Respiratory Tract Infections Global Clinical Trials Review Report, H2, 2015 - Analysis & Opportunities
M2 - Fri Dec 11, 2:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8gxbss/acute_upper) has announced the addition of the "Acute Upper Respiratory Tract Infections Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Acute Upper Respiratory Tract Infections Global Clinical Trials Review, H2, 2015" provides an overview of Acute Upper Respiratory Tract Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Upper Respiratory Tract Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - NPF Materia Medica Holding - Valeant Pharmaceuticals International, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Rose Pharmed Biotechnology Co. - Reckitt Benckiser Group Plc - Novartis AG - Laboratoires Pierre Fabre SA - Daewon Pharm Co. Ltd. For more information visit http://www.researchandmarkets.com/research/8g...cute_upper
VRX.TO: 36.54 (+1.47), NVS: 81.48 (-0.55)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxcczv/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Attention Deficit Hyperactivity Disorder (ADHD) Overview - Therapeutics Development - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - APeT Holding BV - Arbor Pharmaceuticals, LLC. - BCWorld Pharm Co. Ltd. - Collegium Pharmaceutical, Inc. - Curemark, LLC - Domain Therapeutics SA - DURECT Corporation - H. Lundbeck A/S - Heptares Therapeutics Limited - Highland Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Luc Therapeutics, Inc. - Medgenics Inc. - Merck & Co., Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Neurovance, Inc. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/jx...on_deficit
KMPH: 4.56 (+0.01), MDGN: 5.54 (+0.16), ADHD: 4.65 (-0.05), SUPN: 26.17 (+0.15), COLL: 15.48 (+0.18), DRRX: 1.70 (-0.04), NEOS: 7.14 (+0.25), NDRM: 17.37 (-0.38), MRK: 62.96 (-0.06), SHPG: 203.05 (-1.17), ITCI: 42.40 (+1.53)
Mycoplasma Pneumoniae Infections Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Tue Dec 29, 9:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/z8tvk9/mycoplasma) has announced the addition of the "Mycoplasma Pneumoniae Infections Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Mycoplasma Pneumoniae Infections Global Clinical Trials Review, H2, 2015" provides an overview of Mycoplasma Pneumoniae Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Mycoplasma Pneumoniae Infections. It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Cempra, Inc. - KYORIN Holdings, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Shenzhen Kexing Biotech Co., Ltd. - Pfizer Inc. - Fujifilm Holdings Corporation - Daiichi Sankyo Company, Limited For more information visit http://www.researchandmarkets.com/research/z8tvk9/mycoplasma
PFE: 34.26 (+0.11), CEMP: 25.21 (+0.61)
Acute Upper Respiratory Tract Infections Global Clinical Trials Review Report, H2, 2015 - Analysis & Opportunities
M2 - Fri Dec 11, 2:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8gxbss/acute_upper) has announced the addition of the "Acute Upper Respiratory Tract Infections Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Acute Upper Respiratory Tract Infections Global Clinical Trials Review, H2, 2015" provides an overview of Acute Upper Respiratory Tract Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Upper Respiratory Tract Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - NPF Materia Medica Holding - Valeant Pharmaceuticals International, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Rose Pharmed Biotechnology Co. - Reckitt Benckiser Group Plc - Novartis AG - Laboratoires Pierre Fabre SA - Daewon Pharm Co. Ltd. For more information visit http://www.researchandmarkets.com/research/8g...cute_upper
VRX.TO: 36.54 (+1.47), NVS: 81.48 (-0.55)
(0)
(0)Scroll down for more posts ▼